Assessment of Serum Uric Acid Levels According to Sex and Stage for Patients with Alzheimer-type Dementia

yazar, hulya; YAZAR, Tamer

doi:10.4274/tnd.galenos.2019.85698

Assessment of Serum Uric Acid Levels According to Sex and Stage for Patients with Alzheimer-type Dementia

Tamer YAZAR, (Sağlık Bakanlığı)

Hülya Olgun YAZAR (Ordu Üniversitesi)

Türk Nöroloji Dergisi

2 0

Yıl: 2019 Cilt: 25 Sayı: 2 Sayfa Aralığı: 76 - 81 Metin Dili: İngilizce DOI: 10.4274/tnd.galenos.2019.85698 İndeks Tarihi: 01-05-2020

Assessment of Serum Uric Acid Levels According to Sex and Stage for Patients with Alzheimer-type Dementia

Öz:

Objective: The aim of this study was to identify serum uric acid (UA) concentrations according to disease stage in patients with Alzheimer-type dementia (AD),and to collect data related to the hypothesis that oxidative stress is effective on the etiopathogenesis and progression of disease stage.Materials and Methods: The study was conducted with 180 patients who were categorized into disease stages in accordance with the Clinical Dementia RatingScale (CDR) and 150 healthy individuals of the same age group. In our retrospective study, patients who showed more than one cognitive deficit and diagnosedwith possible AD according to the diagnostic criteria of National Institute of Neurological and Communicative Disorders and Stroke-Alzheimer’s Disease andRelated Disorders Association were administered the CDR, Mini-Mental Test (MMSE), Geriatric Depression Rating Scale (GDRS), and individuals in the controlgroup were administered the MMSE and GDRS. Venous blood samples for biochemical studies were collected after 12-14 hours of fasting in the patient andcontrol groups.Results: In patients diagnosed as having AD, it was found that there was a statistically significant increase in age and duration of disease parallel with theprogression of disease stages, and a decrease in UA and albumin concentrations in both males and females (p<0.05).Conclusion: Our study supports the hypothesis that the decrease detected in serum UA concentrations in parallel with the progression of disease stages isdirectly related to the pathogenesis of AD.For the identification of chronic progressive diseases such as AD and to take precautions, the identification of variations in easily accessible and low-cost parameterssuch as serum albumin and UA concentrations in the early stages becomes important. In future years, when neuroprotective and neuro-restorative treatmentoptions are available, identification of serum UA values as a marker of disease progression and knowledge of the association between serum UA concentrations anddisease stage in our data will guide and support research into disease etiology.

Anahtar Kelime:

Konular: Nörolojik Bilimler

Alzheimer Tipi Demans Tanılı Hastalarda Cinsiyete ve Evrelere Göre Serum Ürik Asit Seviyelerinin Değerlendirilmesi

Öz:

Amaç: Alzheimer tipi demans (AH) tanılı hastalarda hastalık evresine göre serum ürik asit (ÜA) seviyelerinin tespiti ile oksidatif stresin hastalık etiyolojisindeki rolüne ve hastalık evresinin ilerlemesi üzerindeki olası etkilerine yönelik veriler toplanması amaçlanmıştır. Gereç ve Yöntem: Çalışma, Clinical Dementia Rating Scale (CDR) kriterlerine göre evrelere ayrılan 180 hasta ve hastalarla aynı yaş aralığında sağlıklı 150 birey ile gerçekleştirilmiştir. Retrospektif olarak yapılan çalışmamızda, birden fazla bilişsel alanda bozukluk gösteren ve National Institute of Neurological and Communicative Disorders and Stroke-Alzheimer’s Disease and Related Disorders Association tanı kriterlerine göre olası AH tanısı konulmuş hastalara CDR, MiniMental Test (MMSE), Geriatrik Depresyon Rating Scale (GDRS), kontrol grubundaki bireylere MMSE ve GDRS uygulanmıştır. Hasta ve kontrol gruplarında 12-14 saat açlıktan sonra biyokimyasal çalışmalar için venöz kan örnekleri alınmıştır. Bulgular: AH tanılılarda, hastalık evrelerindeki artışa paralel olarak kadın ve erkeklerde istatistiksel olarak anlamlı seviyede yaş ve hastalık sürelerinin arttığı, ÜA ve albümin seviyelerinin azaldığı tespit edilmiştir (p<0,05). Sonuç: Çalışmamız, ÜA’nın serum seviyelerindeki hastalık evrelerindeki ilerlemeye paralel olarak tespit edilen azalmanın AH ile doğrudan ilişkili olduğu hipotezini desteklemektedir. AH gibi kronik, ilerleyici hastalıkların başlangıç evrelerinde tespiti ve önlemler alınabilmesi için, serum albümin ve ÜA seviyesi gibi kolay ulaşılabilir, az maliyetli parametrelerdeki değişikliklerin erken dönemde tespiti, AH tanısı konulduktan sonra uygulanan tedavilerin hastalığı önleyici etkilerinin kısıtlılığı dikkate alındığında önem arz etmektedir.

Anahtar Kelime:

Konular: Nörolojik Bilimler

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık

1. Small GW, Gunay I. Geriatric Medicine. In: Rundel JR, Wise MG (eds). Textbook of Consultation-Liaison Psychiatry: Psychiatry in Medically Ill. Washington, American Psychiatric Press, 2005:878-899.
2. Prince MJ, James M, Comas-Herrara A, et al. Improving heathcare for people living with demantia: coverage, quality and costs now and in the future. World Alzheimer Report 2016. London: Alzheimer Disease International, 2016. 131p.
3. Koca E, Taşkapılıoğlu Ö, Bakar M. Caregiver Burden in Different Stages of Alzheimer’s Disease. Noro Psikiyatr Ars 2017;54:82-86.
4. Schirinzi T, Lazzaro GD, Colona CL, et al. Assesment of serum uric acid as risk factor for tauopathies. J Neural Transm 2017;124:1105-1108.
5. Cankurtaran M, Yesil Y, Kuyumcu ME, et al. Altered levels of homocysteine and serum natural antioxidants links oxidative damage to Alzheimer's disease. J Alzheimers Dis 2013;33:1051-1058.
6. El Ridi R, Tallima H. Physiological functions and pathogenic potential of uric acid: A review. J Adv Res 2017;8;487-493.
7. Euser SM, Hofman A, Westendorp RG, Breteler MM. Serum uric acid and cognitive function and dementia. Brain 2009;132:377-382.
8. Polidori MC, Mecocci P. Plasma susceptibility to free radical-induced antioxidant consumption and lipid peroxidation is increased in very old subjects with Alzheimer disease. J Alzheimers Dis 2002;4:517-522.
9. Kim TS, Pae CU, Yoon SJ, et al. Decreased plasma antioxidants in patients with Alzheimer's disease. Int J Geriatr Psychiatry 2006;21:344-348.
10. Irizarry MC, Raman R, Schwarzschild MA, et al. Plasma urate and progression of mild cognitive impairment. Neurodegener Dis 2009;6:23-28.
11. Cascalheira JF, Joao SS, Pinhancos SS, et al. Serum homocysteine: interplay with other circulating and genetic factors in association to Alzheimer’s type dementia. Clin Biochem Clin Biochem 2009;42:783-790.
12. Ahlskog JE, Uitti RJ, Low PA, et al. No evidence for systemic oxidant stress in Parkinson's or Alzheimer's disease. Mov Disord 1995;10:566-573.
13. Chen X, Guo X, Huang R, et al. Serum uric acid levels in patients with Alzheimer’s Disease: A meta-aanalysis. PLoS One 2014;9:e94084.
14. McKhann G, Drachman D, Folstein M, et al. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984;34:939-944.
15. Hughes CP, Berg L, Danziger WL, et al. A new clinical scale for the staging of dementia. Br J Psychiatry 1982;140:566-572.
16. Folstein MF, Folstein SE, McHugh PR. Mini-mental state. J Psychiat Research 1975;12:189-198.
17. Güngen C, Ertan T, Eker E, Yaşar Y, Engin F. Standardize Mini Mental Test'in Türk toplumunda hafif demans tanısında geçerlik ve güvenilirliği. Türk Psikiyatri Dergisi 2002;13:273-281.
18. Yesavage JA, Brink TL, Rose TL, et al. Development and validation of a geriatric depression screening scale: a preliminary report. J Psychiatr Res 1982-1983;17:37-49.
19. Ertan T, Eker E, Şar V. Geriatrik Depresyon Ölçeğinin Türk Yaşlı Nüfusunda Geçerlilik Ve Güvenilirliği. Nöropsikiyatri Arşivi 1997;34:62-71.
20. Sağduyu A. Yaşlılar için depresyon ölçeği: Hamilton depresyon ölçeği ile karşılaştırmalı güvenilirlik ve geçerlilik çalışması. Türk Psikiyatri Dergisi1997;8:3-8.
21. Yan MH, Wang X, Zhu X. Mitochondrial defects and oxidative stress in Alzheimer disease and Parkinson disease. Free Radic Biol Med 2013;62:90- 10.
22. Lee HP, Pancholi N, Esposito L, et al. Early induction of oxidative stress in mouse model of Alzheimer disease with reduced mitochondrial superoxide dismutase activity. PLoS One 2012;7:e28033.
23. Clark TA, Lee HP, Rolston RK, et al. Oxidative Stress and its Implications for Future Treatments and Management of Alzheimer Disease. Int J Biomed Sci 2010;6:225-227.
24. Butterfield DA. Oxidative stress in Alzheimer disease: synergy between the Butterfield and Markesbery laboratories. Neuromolecular Med 2011;13:19- 22.
25. Gella A, Durany N. Oxidative stress in Alzheimer disease. Cell Adh Migr 2009;3:88-93.
26. Moreira PI, Siedlak SL, Aliev G, et al. Oxidative stress mechanisms and potential therapeutics in Alzheimer disease. J Neural Transm (Vienna) 2005;112:921-932.
27. Maiese K, Chong ZZ. Insights into oxidative stress and potential novel therapeutic targets for Alzheimer disease. Restor Neurol Neurosci 2004;22:87-104.
28. Mecocci P. Oxidative stress in mild cognitive impairment and Alzheimer disease: a continuum. J Alzheimers Dis 2004:159-163.
29. Christen Y. Oxidative stress and Alzheimer disease. Am J Clin Nutr 2000;71:621S-629S.
30. Huang W, Zhang X, Chen W. Role of oxidative stress in Alzheimer disease. Biomed Rep 2016;4:519-522.
31. Cipriani S, Chen X, Schwarzschild MA. Urate: a novel biomarker of Parkinson’s disease risk, diagnosis and prognosis. Biomark Med 2010;4:701- 712.
32. Sakuta H, Suzuki K, Miyamoto T, et al. Serum uric acid levels in Parkinson’s disease and related disorders. Brain Behav 2017;7:e00598.
33. Vieru E, Köksal A, Mutluay M, et al. The relation of serum uric acid levels with L-Dopa treatment and progression in patients with Parkinson’s disease. Neurol Sci 2016;37:743-747.
34. Pu Z, Xu W, Lin Y, He J, Huang M. Oxidative Stress Markers and Metal Ions are Correlated With Cognitive Function in Alzheimer's Disease. Am J Alzheimers Dis Other Demen 2017;32:353-359.
35. Ye BS, Lee WW, Ham JH, et al; Alzheimer's Disease Neuroimaging Initiative. Does serum uric acid act as a modulator of cerebrospinal fluid Alzheimer's disease biomarker related cognitive decline? Eur J Neurol 2016;23:948-957.
36. Latourte A, Bardin T, Richette P. Uric acid and cognitive decline: a doubleedge sword? Curr Opin Rheumatol 2018;30:183-187.
37. Xue L, Liu Y, Xue H, et al. Low uric acid is a risk factor in mild cognitive impairment .Neuropsychiatr Dis Treat 2017:13;2363-2367.
38. Polidori MC, Mattioli P, Aldred S, et al. Plasma antioxidant status, immunoglobulin g oxidation and lipid peroxidation in demented patients: relevance to Alzheimer disease and vascular dementia. Dement Geriatr Cogn Disord 2004;18:265-270.
39. Zafrilla P, Mulero J, Xandri JM, et al. Oxidative stress in Alzheimer patients in different stages of the disease. Curr Med Chem 2006;13:1075-1083.
40. Carantoni M, Zuliani G, Munari MR, et al. Alzheimer disease and vascular dementia: relationships with fasting glucose and insulin levels. Dement Geriatr Cogn Disord 2000;11:176-180.
41. Maesaka JK, Wolf-Klein G, Piccione JM, Ma CM. Hypouricemia, abnormal renal tubular urate transport, and plasma natriuretic factor(s) in patients with Alzheimer's disease. J Am Geriatr Soc 1993;41:501-506.
42. Can M, Varlibas F, Guven B, Akhan O, Yuksel GA. Ischemia modified albumin and plasma oxidative stress markers in Alzheimer's disease. Eur Neurol 2013;69:377-380.
43. Du N, Xu D, Hou X, et al. Inverse association between serum uric acid levels and Alzheimer’ disease risk. Mol Neurobiol 2016;53:2594-2599
44. Iuliano L, Monticolo R, Straface G, et al. Vitamin E and enzymatic/oxidative stress-driven oxysterols in amnestic mild cognitive impairment subtypes and Alzheimer's disease. J Alzheimers Dis 2010;21:1383-1392.
45. Cervellati C, Cremonini E, Bosi C, et al. Systemic oxidative stress in older patients with mild cognitive impairment or late onset Alzheimer's disease. Curr Alzheimer Res 2003;10:365-372.
46. Kueider AM, An Y, Tanaka T, et al. Sex-Dependent Associations of Serum Uric Acid with Brain Function During Aging. J Alzheimers Dis 2017;60:699-706.

APA	YAZAR T, yazar h (2019). Assessment of Serum Uric Acid Levels According to Sex and Stage for Patients with Alzheimer-type Dementia. , 76 - 81. 10.4274/tnd.galenos.2019.85698
Chicago	YAZAR Tamer,yazar hulya Assessment of Serum Uric Acid Levels According to Sex and Stage for Patients with Alzheimer-type Dementia. (2019): 76 - 81. 10.4274/tnd.galenos.2019.85698
MLA	YAZAR Tamer,yazar hulya Assessment of Serum Uric Acid Levels According to Sex and Stage for Patients with Alzheimer-type Dementia. , 2019, ss.76 - 81. 10.4274/tnd.galenos.2019.85698
AMA	YAZAR T,yazar h Assessment of Serum Uric Acid Levels According to Sex and Stage for Patients with Alzheimer-type Dementia. . 2019; 76 - 81. 10.4274/tnd.galenos.2019.85698
Vancouver	YAZAR T,yazar h Assessment of Serum Uric Acid Levels According to Sex and Stage for Patients with Alzheimer-type Dementia. . 2019; 76 - 81. 10.4274/tnd.galenos.2019.85698
IEEE	YAZAR T,yazar h "Assessment of Serum Uric Acid Levels According to Sex and Stage for Patients with Alzheimer-type Dementia." , ss.76 - 81, 2019. 10.4274/tnd.galenos.2019.85698
ISNAD	YAZAR, Tamer - yazar, hulya. "Assessment of Serum Uric Acid Levels According to Sex and Stage for Patients with Alzheimer-type Dementia". (2019), 76-81. https://doi.org/10.4274/tnd.galenos.2019.85698

APA	YAZAR T, yazar h (2019). Assessment of Serum Uric Acid Levels According to Sex and Stage for Patients with Alzheimer-type Dementia. Türk Nöroloji Dergisi, 25(2), 76 - 81. 10.4274/tnd.galenos.2019.85698
Chicago	YAZAR Tamer,yazar hulya Assessment of Serum Uric Acid Levels According to Sex and Stage for Patients with Alzheimer-type Dementia. Türk Nöroloji Dergisi 25, no.2 (2019): 76 - 81. 10.4274/tnd.galenos.2019.85698
MLA	YAZAR Tamer,yazar hulya Assessment of Serum Uric Acid Levels According to Sex and Stage for Patients with Alzheimer-type Dementia. Türk Nöroloji Dergisi, vol.25, no.2, 2019, ss.76 - 81. 10.4274/tnd.galenos.2019.85698
AMA	YAZAR T,yazar h Assessment of Serum Uric Acid Levels According to Sex and Stage for Patients with Alzheimer-type Dementia. Türk Nöroloji Dergisi. 2019; 25(2): 76 - 81. 10.4274/tnd.galenos.2019.85698
Vancouver	YAZAR T,yazar h Assessment of Serum Uric Acid Levels According to Sex and Stage for Patients with Alzheimer-type Dementia. Türk Nöroloji Dergisi. 2019; 25(2): 76 - 81. 10.4274/tnd.galenos.2019.85698
IEEE	YAZAR T,yazar h "Assessment of Serum Uric Acid Levels According to Sex and Stage for Patients with Alzheimer-type Dementia." Türk Nöroloji Dergisi, 25, ss.76 - 81, 2019. 10.4274/tnd.galenos.2019.85698
ISNAD	YAZAR, Tamer - yazar, hulya. "Assessment of Serum Uric Acid Levels According to Sex and Stage for Patients with Alzheimer-type Dementia". Türk Nöroloji Dergisi 25/2 (2019), 76-81. https://doi.org/10.4274/tnd.galenos.2019.85698